Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.85B
Last updated: Nov 17, 2026 at 11:06 AM ET
Royalty Pharma Plc (RPRX) Earnings: Report Dates and Results
Royalty Pharma Plc (RPRX) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Royalty Pharma Plc reported EPS of $1.21, above the $1.18 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RPRX has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.1% above the $1.47 reported for the quarter ended Dec 31, 2025.
RPRX Earnings Call
The latest RPRX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, RPRX beat 25, missed 3 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $690.10M, up 13.3% from $609.29M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.21 | $1.18 | $1.15 - $1.22 | +2.54% | Beat | +3.4% | 6 | 1 up, 1 down | Nov 4, 2026 | $690.10M |
| Jun 30, 2026 | $1.32 | $1.27 | $1.23 - $1.33 | +3.94% | Beat | +15.8% | 6 | 2 up, 1 down | Aug 5, 2026 | $674.14M |
| Mar 31, 2026 | $1.30 | $1.18 | $1.17 - $1.19 | +10.17% | Beat | +22.6% | 3 | 1 up, 1 down | May 6, 2026 | $630.58M |
| Dec 31, 2025 | $1.47 | $1.33 | $1.13 - $1.41 | +10.53% | Beat | +27.8% | 6 | 2 up, 1 down | Feb 11, 2026 | $621.99M |
| Sep 30, 2025 | $1.17 | $1.11 | $0.87 - $1.16 | +5.41% | Beat | +12.5% | 6 | 1 up, 1 down | Nov 5, 2025 | $609.29M |
| Jun 30, 2025 | $1.14 | $1.03 | $0.86 - $1.13 | +10.68% | Beat | +18.7% | 6 | 1 up, 2 down | Aug 6, 2025 | $578.66M |
| Mar 31, 2025 | $1.06 | $0.95 | $0.86 - $1.04 | +11.58% | Beat | +8.2% | 4 | 0 up, 1 down | May 8, 2025 | $568.25M |
| Dec 31, 2024 | $1.15 | $1.05 | $0.65 - $1.24 | +9.52% | Beat | -24.3% | 7 | 1 up, 1 down | Feb 11, 2025 | $593.64M |
| Sep 30, 2024 | $1.04 | $0.93 | $0.70 - $1.05 | +11.83% | Beat | +31.6% | 7 | 1 up, 0 down | Nov 6, 2024 | $564.69M |
| Jun 30, 2024 | $0.96 | $0.97 | $0.92 - $1.07 | -1.03% | Miss | +14.3% | 6 | 1 up, 1 down | Aug 8, 2024 | $537.27M |
| Mar 31, 2024 | $0.98 | $0.98 | $0.91 - $1.07 | 0.00% | In line | -38.8% | 5 | 1 up, 1 down | May 9, 2024 | $567.98M |
| Dec 31, 2023 | $1.52 | $1.00 | $0.92 - $1.11 | +52.00% | Beat | -2.6% | 6 | 3 up, 0 down | Feb 15, 2024 | $596.07M |
| Sep 30, 2023 | $0.79 | $0.77 | $0.68 - $0.86 | +2.60% | Beat | +8.2% | 5 | 1 up, 0 down | Nov 8, 2023 | $536.31M |
| Jun 30, 2023 | $0.84 | $0.81 | $0.72 - $0.84 | +3.70% | Beat | +6.3% | 5 | 1 up, 0 down | Aug 8, 2023 | $538.20M |
| Mar 31, 2023 | $1.60 | $1.27 | $0.83 - $1.52 | +25.98% | Beat | +166.7% | 6 | 2 up, 0 down | May 9, 2023 | $683.97M |
| Dec 31, 2022 | $1.56 | $1.46 | $1.31 - $1.61 | +6.85% | Beat | +95.0% | 8 | 3 up, 0 down | Feb 15, 2023 | $565.75M |
| Sep 30, 2022 | $0.73 | $0.71 | $0.68 - $0.75 | +2.82% | Beat | 0.0% | 8 | 2 up, 0 down | Nov 8, 2022 | $573.46M |
| Jun 30, 2022 | $0.79 | $0.78 | N/A | +1.28% | Beat | +11.3% | N/A | 0 up, 2 down | Aug 4, 2022 | $535.96M |
| Mar 31, 2022 | $0.60 | $0.72 | $0.69 - $0.78 | -16.67% | Miss | -10.4% | 6 | 0 up, 1 down | May 5, 2022 | $562.05M |
| Dec 31, 2021 | $0.80 | $0.78 | $0.70 - $0.80 | +2.56% | Beat | +14.3% | 6 | N/A | Feb 15, 2022 | $575.70M |
| Sep 30, 2021 | $0.73 | $0.70 | $0.63 - $0.72 | +4.29% | Beat | +12.3% | 5 | N/A | Nov 10, 2021 | $585.77M |
| Jun 30, 2021 | $0.71 | $0.71 | $0.64 - $0.72 | 0.00% | In line | +16.4% | 6 | N/A | Aug 11, 2021 | $554.96M |
| Mar 31, 2021 | $0.67 | $0.65 | $0.61 - $0.68 | +3.08% | Beat | -83.0% | 6 | N/A | May 11, 2021 | $573.03M |
| Dec 31, 2020 | $0.70 | $0.70 | $0.63 - $0.72 | 0.00% | In line | N/A | 7 | N/A | Feb 17, 2021 | $572.14M |
| Sep 30, 2020 | $0.65 | $0.59 | $0.57 - $0.62 | +10.17% | Beat | N/A | 6 | N/A | Nov 10, 2020 | $538.40M |
| Jun 30, 2020 | $0.61 | $0.60 | $0.58 - $0.63 | +1.67% | Beat | N/A | 7 | N/A | Aug 12, 2020 | $510.93M |
| Mar 31, 2020 | $3.94 | $0.52 | N/A | +657.69% | Beat | N/A | N/A | N/A | Jun 17, 2020 | $500.88M |
| Sep 30, 2017 | -$0.05 | -$0.28 | N/A | +82.14% | Beat | N/A | N/A | N/A | Sep 30, 2017 | N/A |
| Jun 30, 2017 | -$0.08 | -$0.22 | N/A | +63.64% | Beat | N/A | N/A | N/A | Jun 30, 2017 | N/A |
| Mar 31, 2017 | -$0.22 | -$0.14 | N/A | -57.14% | Miss | N/A | N/A | N/A | Mar 31, 2017 | N/A |
| Dec 31, 2016 | -$0.16 | -$0.17 | N/A | +5.88% | Beat | N/A | N/A | N/A | Dec 31, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.84, up 17.2% from the year before. It was -$0.16 for the year ended Dec 31, 2016, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.84 | +17.2% |
| Dec 31, 2024 | $4.13 | -13.1% |
| Dec 31, 2023 | $4.75 | +29.1% |
| Dec 31, 2022 | $3.68 | +26.5% |
| Dec 31, 2021 | $2.91 | -47.6% |
| Dec 31, 2020 | $5.55 | N/A |
| Dec 31, 2016 | -$0.16 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,724 | 14 | |
| 2026Q2 | Jun 30, 2026 | 5,693 | 14 | |
| 2026Q1 | Mar 31, 2026 | 6,377 | 14 | |
| 2025Q4 | Dec 31, 2025 | 8,588 | 14 | |
| 2025Q3 | Sep 30, 2025 | 5,048 | 11 | |
| 2025Q2 | Jun 30, 2025 | 6,263 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,110 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,076 | 12 |
2026Q3 Earnings Call
Opening remarks
George Grofik Senior Vice President, Head of Investor Relations and Communications Good morning, and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's third quarter results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com. On Slide 2, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from these statements. We refer you to our most recent 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements. Non-GAAP liquidity measures will be used to help you understand our financial results, and the reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website. And with that, please advance to Slide 3. Our speakers on the call today are Pablo Legorreta, Chief Executive Officer and Chairman of the Board; Marshall Urist, EVP, Head of Research and Investments; and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights, after which Marshall will provide a portfolio update and Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session when we will be joined by Chris Hite, Chairman, Partnering and Investments. And with that, I'd like to turn the call over to Pablo.
Pablo Legorreta Chief Executive Officer and Chairman of the Board Thank you, George, and welcome to everyone on the call. It gives me great pleasure to report another strong quarter in 2026 as we execute towards our goal to be the premier capital allocator in life sciences with consistent compounding growth. Slide 5 summarizes our strong business momentum in the third quarter. Starting with the financials, we delivered 9% growth in Portfolio Receipts, our top line, and also in Royalty Receipts, which are our recurring cash flows. On a year-to-date basis, Royalty Receipts have grown by 12%, reflecting the strength of our diversified portfolio of high-quality royalties. We also maintained attractive returns in our business with return on invested capital of 14.3% and return on invested equity of 20.2%. By combining strong growth and superior returns, we're confident we have a clear path to drive shareholder value creation. Turning to capital allocation. We have deployed $1.6 billion of capital so far this year with an announced value of $1.9 billion. Most recently, we acquired a royalty on Arcutis' Zoryve, an approved therapy for immune diseases of the skin.
Frequently Asked Questions About RPRX
When is Royalty Pharma Plc's next earnings date?
Royalty Pharma Plc's next earnings report is expected for Feb 9, 2027.
Did RPRX beat earnings estimates last quarter?
Yes. Royalty Pharma Plc reported EPS of $1.21 for the quarter ended Sep 30, 2026, above the $1.18 estimate, a 2.54% surprise.
What EPS do analysts expect from RPRX next quarter?
The consensus EPS estimate for Royalty Pharma Plc for the quarter ending Dec 31, 2026 is $1.56 from 9 analysts, with estimates from $1.36 to $1.72.
How often does RPRX beat earnings estimates?
Royalty Pharma Plc beat the EPS estimate in each of the last 9 quarters, with an average surprise of +8.47%.
RPRX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors